Duncan Williams Asset Management LLC Has $931,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Duncan Williams Asset Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 42.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,439 shares of the company’s stock after purchasing an additional 1,916 shares during the quarter. Duncan Williams Asset Management LLC’s holdings in Johnson & Johnson were worth $931,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Precedent Wealth Partners LLC grew its stake in Johnson & Johnson by 1.6% in the 4th quarter. Precedent Wealth Partners LLC now owns 7,724 shares of the company’s stock valued at $1,117,000 after buying an additional 123 shares during the last quarter. AlphaMark Advisors LLC grew its position in shares of Johnson & Johnson by 26.4% in the fourth quarter. AlphaMark Advisors LLC now owns 1,729 shares of the company’s stock valued at $250,000 after purchasing an additional 361 shares during the last quarter. Olstein Capital Management L.P. increased its stake in shares of Johnson & Johnson by 6.6% in the fourth quarter. Olstein Capital Management L.P. now owns 65,000 shares of the company’s stock worth $9,400,000 after purchasing an additional 4,000 shares during the period. Jacksonville Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at approximately $439,000. Finally, Insight Inv LLC grew its holdings in Johnson & Johnson by 6.4% in the 4th quarter. Insight Inv LLC now owns 11,424 shares of the company’s stock valued at $1,652,000 after buying an additional 685 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Bank of America decreased their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Finally, Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.44.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 1.5 %

Shares of JNJ opened at $150.63 on Wednesday. The business’s 50 day simple moving average is $147.81 and its 200-day simple moving average is $156.12. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a market capitalization of $362.65 billion, a P/E ratio of 22.65, a PEG ratio of 2.45 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.29%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.